链接：https://www.abinscience.cn/product/71/1350.html
名称：Research Grade Palivizumab 帕利珠单抗
别名：Palivizumab ，帕利珠单抗，抗体，MEDI-493
CAS: 188039-54-5
货号：VK421016
适用物种：HRSV-A
寄主物种：Humanized
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG1, kappa
应用：Research Grade Biosimilar
UniProt：P03420
靶点：F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
产品介绍：Palivizumab (MEDI 493) 是一种人源化呼吸道合胞病毒 (RSV) 单克隆抗体。Palivizumab 可以结合 RSV F 蛋白， Kd 值为 1.4 nM。Palivizumab 可以预防棉鼠的呼吸道合胞病毒感染。abinScience产品具有亲和力高，灵敏度高，特异性好，稳定性强等优势。
产品购买联系方式：027-87433958/17302791434
参考文献：
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. PMID: 34783356
Palivizumab. PMID: 10473022
Palivizumab prophylaxis in preterm infants. PMID: 28219614
Palivizumab: an overview. PMID: 10707171
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. PMID: 35235733
Palivizumab: where to from here? PMID: 19063700
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. PMID: 37018470
Palivizumab Use in the NICU: 1999-2020. PMID: 35730329
Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. PMID: 37357729
RSV Prevention in All Infants: Which Is the Most Preferable Strategy? PMID: 35572550
Guidance for palivizumab prophylaxis and implications for compliance. PMID: 34547834
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. PMID: 20166098
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. PMID: 36634694
Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants. PMID: 36748923
Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. PMID: 31060948
Adherence and outcomes: a systematic review of palivizumab utilization. PMID: 29130355
Respiratory Syncytial Virus Bronchiolitis in Children. PMID: 28084708
Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review. PMID: 37440737
Palivizumab prophylaxis in 'late preterm' newborns. PMID: 20695756
Bronchiolitis: an update on management and prophylaxis. PMID: 31059347
Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. PMID: 24231153
Neutralizing epitopes of RSV and palivizumab resistance in Japan. PMID: 28867684
Palivizumab and Long-term Outcomes in Cystic Fibrosis. PMID: 31239289
Palivizumab in the prevention of respiratory syncytial virus disease. PMID: 12387675
Palivizumab in the prophylaxis of respiratory syncytial virus infection. PMID: 16207163
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. PMID: 33107769
Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017. PMID: 32859612
Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study. PMID: 38116923
New strategies for the prevention of respiratory syncytial virus (RSV). PMID: 36174288
RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future. PMID: 36811330
Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. PMID: 33748434
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). PMID: 26670908
Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. PMID: 27618642
Palivizumab in congenital heart disease: should international guidelines be revised? PMID: 17961086
Administration of Palivizumab in the NICU. PMID: 27164941
Improving the prescribing of palivizumab. PMID: 29863814
The potential impact of palivizumab on pediatric airway reconstruction. PMID: 16360816
Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. PMID: 28423192
Treatment of respiratory syncytial virus with palivizumab: a systematic review. PMID: 21080142
Utilization and efficacy of palivizumab for children with Down syndrome. PMID: 31961027
详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn
【英文】https://www.abinscience.com
武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。
返回顶部
